Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 19/20 | 0.72 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22463747 | 0.85 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL22493221 | 0.85 | ADORA2A (0.76) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL22730067 | 0.77 | ADORA3 (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL659393 | 0.74 | ADORA2A (0.60) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL9313310 | 0.74 | ADORA3 (0.58) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL22463741 | 0.74 | ADORA3 (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL22463754 | 0.73 | ADORA3 (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL22730068 | 0.73 | ADORA3 (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL22463748 | 0.71 | ADORA3 (1.00) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL22463746 | 0.71 | ADORA3 (1.00) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481836-B1 | NOVEL THIAZOLO[5,4-D]PYRIMIDINE DERIVATIVES AS INVERSE AGONISTS OF A2A ADENOSINE RECEPTORS | UNIV DEGLI STUDI DI FIRENZE (IT) | 2020-12-09 | — | — | EP | disclosed |
| US-20200308192-A1 | NOVEL THIAZOLO[5,4-D]PYRIMIDINE DERIVATIVES AS INVERSE AGONISTS OF A2A ADENOSINE RECEPTORS | UNIVERSITA DEGLI STUDI DI FIRENZE (IT) | 2020-10-01 | — | — | US | disclosed |
| US-20200308192-A1 | NOVEL THIAZOLO[5,4-D]PYRIMIDINE DERIVATIVES AS INVERSE AGONISTS OF A2A ADENOSINE RECEPTORS | UNIVERSITA DEGLI STUDI DI FIRENZE (IT) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308192-A1 | NOVEL THIAZOLO[5,4-D]PYRIMIDINE DERIVATIVES AS INVERSE AGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.